Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Metastatic IBC or Non-IBC TNBC
NCT02411656Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2015
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in inflammatory breast cancer (IBC), triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2015; status: active, not recruiting.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02411656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411656.